-
Clinical implications of natalizumab Fab-arm exchange in patients with multiple sclerosis
Gelissen, L. M. Y., van den Berg, S. P. H., Toorop, A. A., Wijburg, M. T., Tallantyre, E. C., Derksen, N. I. L., Loeff, F. C., Killestein, J. & NEXT-MS study group, Jan 2026, In: Frontiers in immunology. 17, p. 1796273 1796273.Research output: Contribution to journal › Article › Academic › peer-review
-
Low natalizumab trough concentrations are associated with reduced seroconversion of the John Cunningham virus in natalizumab-treated patients with multiple sclerosis
Gelissen, L. M. Y., Toorop, A. A., Schipper, P. M., Hoitsma, E., Zeinstra, E. M. P. E., Van Rooij, L. C., Van Munster, C. E. P., Vennegoor, A., Mostert, J., Wokke, B., Kalkers, N. F., Hoogervorst, E. L. J., Van Eijk, J., Roosendaal, C. M., Kragt, J. J., Eurelings, M., Van Genugten, J., Nielsen, J., Sinnige, L. G. F. & Kloosterziel, M. E. & 11 others, , 1 Nov 2025, In: Journal of Neurology, Neurosurgery and Psychiatry. 96, 11, p. 1038-1045 8 p.Research output: Contribution to journal › Article › Academic › peer-review
-
Pharmacokinetic Model-Informed Precision Dosing of Natalizumab in Multiple Sclerosis
van den Berg, S. P. H., Toorop, A. A., Hooijberg, F., Wolbink, G., Voelkner, N. M. F., Gelissen, L. M. Y., Killestein, J., van Kempen, Z. L. E., Dorlo, T. P. C. & Rispens, T., Jun 2025, In: CPT: Pharmacometrics and Systems Pharmacology. 14, 6, p. 1032-1041 10 p.Research output: Contribution to journal › Article › Academic › peer-review
- All publications
